Taiho Ventures co-led a series A round for the MIT spinout, which was incubated by MPM Capital.

US-based circular RNA therapy developer Orna Therapeutics launched with more than $100m in funding yesterday to commercialise research undertaken at Massachusetts Institute of Technology. The total includes an $80m series A round co-led by Taiho Ventures, the corporate venturing unit of pharmaceutical firm Taiho, F2 Ventures and MPM Capital. Pharmaceutical firms Astellas, Gilead and Novartis…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.